Liver Transplant Recipients and 30-Second Lie-to-Sit Test

January 15, 2026 updated by: BÜŞRA CANDİRİ, Inonu University

Assessment of Functional Capacity in Liver Transplant Recipients Using the 30-Second Lie-to-Sit Test

The aim of this study is to assess functional capacity in liver transplant recipients using the 30-second lie-to-sit test and to examine the relationships between functional capacity and variables such as muscle strength, upper and lower extremity function, exercise capacity, and perceived exertion.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Participants' demographic and clinical characteristics, including age, gender, BMI, waist circumference, and relevant clinical data, will be recorded. Functional capacity will also be assessed using the 30-second sit-to-stand test, the 2-minute walk test, and upper and lower extremity functional scales (UEFI-15, AEFÖ), with perceived exertion measured using the Modified Borg Scale. Muscle strength will be measured isometrically with a dynamometer for the quadriceps, deltoid, trunk flexor/extensor muscles, and handgrip. The obtained data will provide a comprehensive evaluation of muscle strength and functional status, contributing to individualized rehabilitation planning.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
34

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

liver transplant recipients

Description

Inclusion Criteria:

  • Adults aged 18-65 years
  • Diagnosed with end-stage liver disease and listed for liver transplantation
  • Ability to speak, understand, and write in Turkish
  • No mental disorders
  • Voluntary participation with informed consent

Exclusion Criteria:

  • Pulmonary, neurological, or cardiac diseases that may interfere with adherence to the assessment protocol
  • Difficulty complying with the assessment program
  • Musculoskeletal problems
  • History of regular physical activity
  • Multiple organ failure
  • Cognitive impairment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
30-second lie-to-sit test
Time Frame: 24 hours
In this test, participants will be asked to start from a supine position with their head and arms supported and move to a sitting position as quickly as possible. They will be allowed to use one hand and, if necessary, a thin cushion to help them sit up. The number of repetitions performed within 30 seconds will be recorded.
24 hours

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Waist Circumference
Time Frame: 24 hours
Waist circumference will be measured in centimeters at the narrowest point between the lowest rib and the upper border of the pelvis while the participant is standing, and the value will be recorded.
24 hours
Modified Borg Scale
Time Frame: 24 hours
Following the 30-second lie-to-sit test, the modified Borg scale will be used to assess participants' perceived exertion levels.This scale is a standard tool that allows individuals to subjectively assess their level of exertion during physical activity or exercise, rated from 0 (no exertion) to 10 (maximum exertion).
24 hours
30-second sit-to-stand test
Time Frame: 24 hours
The 30-second sit-to-stand test will be used to assess participants' lower extremity muscle strength and functional capacity. In this test, the participant sits with their back against a chair, feet flat on the floor, and arms crossed over the chest, and stands up and sits down as many times as possible within 30 seconds. Hands should not touch the chair during the test, and only full, complete repetitions are counted. The total number of repetitions at the end of the test will be recorded.
24 hours
Quadriceps muscle strength
Time Frame: 24 hours
Quadriceps muscle strength will be measured isometrically using a hand-held dynamometer. The participant will be seated with the knees flexed at 90°. The dynamometer will be placed on the front of the leg at ankle level, and the participant will be asked to lift the leg with maximal effort. Three measurements will be taken for each leg, and the average value will be recorded.
24 hours
Deltoid muscle strength
Time Frame: 24 hours
Isometric strength of the deltoid muscle will be assessed using a hand-held dynamometer. The participant will be seated with the shoulder positioned at 90° abduction and the elbow slightly flexed. The dynamometer will be placed on the lateral side of the upper arm at elbow level, and the participant will perform maximum-effort shoulder abduction. Three measurements will be taken for each extremity, and the average value will be recorded.
24 hours
Trunk flexion strength
Time Frame: 24 hours
The isometric trunk flexion strength test will be performed with the participant positioned supine, with the knees extented or the hips flexed at 30°. The dynamometer will be placed below the suprasternal notch of the sternum. The participant will place their hands on the opposite acromions and perform isometric trunk flexion.
24 hours
Trunk extension strength
Time Frame: 24 hours
The isometric trunk extension strength, the participant will be positioned prone while lying down. The dynamometer will be placed at the T4 level, and the participant will be asked to perform maximum isometric trunk extension. In each test position, participants will first perform a submaximal trial, followed by three correct repetitions, and the average value will be recorded.
24 hours
Handgrip strength
Time Frame: 24 hours
Handgrip strength will be assessed using a hand dynamometer. Participants will be seated with their shoulders adducted at the sides, elbows flexed at 90°, forearms in a neutral position, and wrists positioned at 0-30° extension and 0-15° ulnar deviation. Three trials will be performed for each hand, with a 30-second rest between trials. For analysis, the average of three measurements for both hands will be recorded.
24 hours
2-minute Walk Test
Time Frame: 24 hours
The 2-minute walk test will be used to assess participants' exercise capacity and physical performance. During the test, participants will walk at a self-selected, safe pace for two minutes, and the distance covered in meters will be recorded.
24 hours
Upper Extremity Functional Index-15 (UEFI-15)
Time Frame: 24 hours
This questionnaire consists of 15 items that assess difficulties in using the upper extremities for activities of daily living. Each item is scored from 0 (cannot do) to 4 (no difficulty). The raw score ranges from 0 to 59 and is converted to a final score ranging from 0 to 100. A higher final score indicates better upper extremity function, providing a comprehensive assessment of functional capacity.
24 hours
Lower Extremity Functional Scale (LEFS)
Time Frame: 24 hours
This questionnaire is important for assessing lower extremity functional capacity and examining activity limitations in various lower extremity disorders. It consists of 20 items, each scored from 0 (extreme difficulty or unable to perform the activity) to 4 (no difficulty). Intermediate values are defined as 1 (quite difficult), 2 (moderately difficult), and 3 (somewhat difficult). The total score ranges from 0 to 80, with higher scores indicating better functional level.
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Inonu University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 8, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 20, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 20, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 15, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 15, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 26, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 26, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 15, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2025/8550

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings